Buscar
Mostrando ítems 1-8 de 8
La INR durante los ictus y las hemorragias en pacientes con fibrilación auricular tratados con antagonistas de la vitamina K
(Elsevier, 2020-07)
[Resumen] Introducción y objetivos. La fibrilación auricular tiene un mal pronóstico asociado fundamentalmente al desarrollo de ictus. A pesar del uso de anticoagulantes, algunos pacientes pueden sufrir ictus y también ...
Do physicians correctly calculate thromboembolic risk scores?: a comparison of concordance between manual and computer‐based calculation of CHADS2 and CHA2DS2‐VASc scores
(Wiley, 2016-03-01)
[Abstract] BACKGROUND: Clinical risk scores, CHADS2 and CHA2 DS2 -VASc scores, are the established tools for assessing stroke risk in patients with atrial fibrillation (AF).
AIM: The aim of this study is to assess concordance ...
Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a “Real-world” Nationwide Registry: Insights From the FANTASIIA Study
(SAGE, 2020-03-31)
[Abstract]
Objective:
To describe major events at follow up in octogenarian patients with atrial fibrillation (AF) according to anticoagulant treatment: direct oral anticoagulants (DOACs) versus vitamin K antagonists ...
Current antiarrhythmic therapy for nonvalvular atrial fibrillation in Spain: data from the FANTASIIA registry
(Elsevier, 2015-06-18)
[Abstract] Introduction and objectives. Recently, there have been many developments in the management of nonvalvular atrial fibrillation, antiarrhythmic and anticoagulant therapy, and nonpharmacological treatment, but these ...
Quality of anticoagulation with vitamin K antagonists
(Wiley, 2015-05-11)
[Abstract] Background. Vitamin K antagonists (VKA) have a narrow therapeutic range, and literature analysis reveals poor quality of anticoagulation control. We sought to assess the prevalence of poor anticoagulant control ...
Choice of new oral anticoagulant agents versus vitamin K antagonists in atrial fibrillation: FANTASIIA study
(SAGE, 2015-07-30)
[Abstract] Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA ...